FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow Breast Cancer By Ogkologos - March 6, 2025 469 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DESTINY-Breast06 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR COVID-19, Vaccines, and the Immune System: Emerging Research from NCI’s SeroNet August 30, 2021 How to Talk With Your Children About Your Metastatic Cancer Prognosis September 2, 2021 After Breast Cancer Diagnosis, Technology Professor Teaches Computers to Read Mammograms April 11, 2019 Workout Wednesday – Back Stretches Part 2 July 29, 2020 Load more HOT NEWS No Clinical Benefit from Nivolumab Plus Ipilimumab Over Nivolumab Alone as... How erectile dysfunction drugs could be the key to overcoming treatment... An Alternative Model for Genetic Testing Delivery Proposed with Posttest Counselling... 24% of Breast Cancers Diagnosed Between Mammograms Could Have Been Detected...
